Compare CRI & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRI | NTLA |
|---|---|---|
| Founded | 1865 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 986.9M |
| IPO Year | 2003 | 2016 |
| Metric | CRI | NTLA |
|---|---|---|
| Price | $31.77 | $9.61 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 5 | 22 |
| Target Price | ★ $28.80 | $19.83 |
| AVG Volume (30 Days) | 1.1M | ★ 4.0M |
| Earning Date | 10-27-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $2,832,687,000.00 | $57,528,000.00 |
| Revenue This Year | $1.58 | $1.96 |
| Revenue Next Year | $0.14 | N/A |
| P/E Ratio | $13.03 | ★ N/A |
| Revenue Growth | N/A | ★ 33.52 |
| 52 Week Low | $23.38 | $5.90 |
| 52 Week High | $56.89 | $28.25 |
| Indicator | CRI | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 47.53 |
| Support Level | $31.80 | $8.74 |
| Resistance Level | $33.38 | $9.55 |
| Average True Range (ATR) | 1.25 | 0.57 |
| MACD | -0.06 | 0.31 |
| Stochastic Oscillator | 18.73 | 83.79 |
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.